John E Stelmach

US Patent:

6809199, Oct 26, 2004

Filed:

Dec 17, 2001

Appl. No.:

10/023231

Inventors:

James B. Doherty - Montvale NJ
John E. Stelmach - Westfield NJ
Meng-Hsin Chen - Westfield NJ
Luping Liu - Lawrenceville NJ
Julianne A. Hunt - Scotch Plains NJ
Rowena D. Ruzck - Old Bridge NJ
Joung L. Goulet - Westfield NJ
David D. Wisnoski - Somerset NJ
Swaminathan Ravi Natarajan - Edison NJ
Kathleen M. Rupprecht - Cranford NJ
Jianming Bao - Scotch Plains NJ
Shouwu Miao - Edison NJ
Xingfang Hong - Westfield NJ
Peter J. Sinclair - Scotch Plains NJ
Florida Kallashi - Yonkers NY

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

C07D23972

US Classification:

544256, 546122

Abstract:

Compounds described by the chemical formula (I) or a pharmaceutically acceptable salt thereof: are inhibitors of p38 useful in the treatment of inflammatory diseases such as arthritis.

US Patent:

7314873, Jan 1, 2008

Filed:

Jun 6, 2003

Appl. No.:

10/517754

Inventors:

James B. Doherty - Montvale NJ, US
Swaminathan R. Natarajan - Scotch Plains NJ, US
John E. Stelmach - Westfield NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 31/5377
A61K 31/491
A61K 31/519
C07D 413/14
C07D 471/14
C07D 487/14
C07D 213/26
C07D 213/30

US Classification:

5142345, 5142641, 51425214, 544279, 544117, 546303, 546334

Abstract:

Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (I) are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

US Patent:

7687534, Mar 30, 2010

Filed:

Oct 2, 2007

Appl. No.:

11/906374

Inventors:

John E. Stelmach - Westfield NJ, US
Emma R. Parmee - Scotch Plains NJ, US
James R. Tata - Westfield NJ, US
Keith G. Rosauer - Laurence Harbor NJ, US
Ronald M. Kim - Summit NJ, US
Amy R. Bittner - Scotch Plains NJ, US
Jiang Chang - Westfield NJ, US
Christopher Joseph Sinz - Cranford NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/404
C07D 209/14

US Classification:

514415, 548511

Abstract:

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

US Patent:

7968589, Jun 28, 2011

Filed:

Feb 9, 2010

Appl. No.:

12/702358

Inventors:

John E. Stelmach - Westfield NJ, US
Emma R. Parmee - Scotch Plains NJ, US
James R. Tata - Westfield NJ, US
Keith G. Rosauer - Laurence Harbor NJ, US
Ronald M. Kim - Summit NJ, US
Amy R. Bittner - Scotch Plains NJ, US
Jiang Chang - Westfield NJ, US
Christopher Joseph Sinz - Cranford NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/404
C07D 209/10

US Classification:

514415, 548511

Abstract:

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

US Patent:

8318760, Nov 27, 2012

Filed:

Mar 17, 2006

Appl. No.:

11/886136

Inventors:

John E. Stelmach - Westfield NJ, US
Keith G. Rosauer - Laurence Harbor NJ, US
Emma R. Parmee - Scotch Plains NJ, US
James R. Tata - Westfield NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A01N 43/40
A01N 43/64
A01N 37/44
A61K 31/41
C07D 213/00
C07D 293/00
C07D 207/00
C07C 61/00
C07C 63/00
C07C 321/00
C07C 323/00

US Classification:

514277, 514359, 514381, 514563, 546 1, 548100, 548400, 562400, 562405, 562427

Abstract:

Substituted aryl and heteroaryl derivatives are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

US Patent:

8436015, May 7, 2013

Filed:

Sep 10, 2009

Appl. No.:

13/063820

Inventors:

Songnian Lin - Monroe NJ, US
Christian P. Stevenson - Hoboken NJ, US
Emma R. Parmee - Scotch Plains NJ, US
Libo Xu - Bridgewater NJ, US
Xibin Liao - Edison NJ, US
Edward Metzger - Somerset NJ, US
Rui Liang - East Brunswick NJ, US
Fengqi Zhang - Edison NJ, US
John E. Stelmach - Westfield NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A01N 43/42
A61K 31/47
C07D 215/00

US Classification:

514312, 546155

Abstract:

Glucagon receptor antagonist compounds of formula I are disclosed:.

US Patent:

8445538, May 21, 2013

Filed:

Dec 9, 2009

Appl. No.:

13/140260

Inventors:

Songnian Lin - Monroe NJ, US
Xibin Liao - Edison NJ, US
Roman Kats-Kagan - Brooklyn NY, US
John E. Stelmach - Westfield NJ, US
Emma R. Parmee - Scotch Plains NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/165
C07C 237/22

US Classification:

514616, 564157

Abstract:

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

US Patent:

20050256117, Nov 17, 2005

Filed:

Jun 11, 2003

Appl. No.:

10/511636

Inventors:

Meng Hsin Chen - Westfield NJ, US
Luping Liu - Palainsboro NJ, US
Peter Meinke - Plainfield NJ, US
Ravi Natarajan - Scotch Plains NJ, US
William Parsons - Belle Mead NJ, US
Min Shu - Green Brook NJ, US
John Stelmach - Westfield NJ, US
Harold Wood - Westfield NJ, US
Fengqi Zhang - Edison NJ, US
David Wisnoski - Lansdale PA, US
James Doherty - Montvale NJ, US

International Classification:

A61K031/5377
A61K031/4439
A61K031/427
C07D417/02
C07D413/02
C07D043/02

US Classification:

514233500, 514370000, 548181000, 514337000, 546270700, 544143000

Abstract:

This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.